Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Discovery of Small Molecules that Inhibit the Disordered Protein, p27Kip1

28 Oct 2015

Abstract excerpt

Disordered proteins are highly prevalent in biological systems, they control myriad signaling and regulatory processes, and their levels and/or cellular localization are often altered in human disease. In contrast to folded proteins, disordered proteins, due to conformational heterogeneity and dynamics, are not considered viable drug targets. We challenged this paradigm by identifying through NMR-based screening...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Epigenetics and DNA Methylation
Share to RNA modifications and cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26507530
DOI: 10.1038/srep15686

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Discovery of Small Molecules that Inhibit the Disordered Protein, p27Kip1PMID 26507530Read ↗

Specific Conformational Dynamics and Expansion Underpin a Multi-Step Mechanism for Specific Binding of p27 with Cdk2/Cyclin A.Semantic proximity Read ↗

Discovery of Nanomolar-Affinity Pharmacological Chaperones Stabilizing the Oncogenic p53 Mutant Y220CSemantic proximity Read ↗

p27Kip1 and human cancers: A reappraisal of a still enigmatic protein.Semantic proximity Read ↗

Computational strategy for intrinsically disordered protein ligand design leads to the discovery of p53 transactivation domain I binding compounds that activate the p53 pathwaySemantic proximity Read ↗

Discovery of Small Molecule Interleukin 17A Inhibitors with Novel Binding Mode and Stoichiometry: Optimization of DNA-Encoded Chemical Library Hits to In Vivo Active CompoundsSemantic proximity Read ↗

p27 allosterically activates cyclin-dependent kinase 4 and antagonizes palbociclib inhibitionSemantic proximity Read ↗

Small molecule binding to disordered proteinsSemantic proximity Read ↗

Cancer-Associated Mutations Perturb the Structure and Interactions of the Intrinsically Disordered p53 Transactivation DomainSemantic proximity Read ↗

p27Kip1 and Tumors: Characterization of CDKN1B Variants Identified in MEN4 and Breast CancerSemantic proximity Read ↗

Chemical genetics approach to restoring p27Kip1 reveals novel compounds with antiproliferative activity in prostate cancer cellsSemantic proximity Read ↗

Chemical validation of a druggable site on Hsp27/HSPB1 using in silico solvent mapping and biophysical methods.Semantic proximity Read ↗

Rational drug design targeting intrinsically disordered proteinsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.